Literature DB >> 17353948

Drug-induced ocular inflammatory diseases.

Frederick W Fraunfelder1.   

Abstract

Ocular inflammation can arise in the form of conjunctivitis, uveitis, episcleritis and scleritis. The uveitides can be subdivided by anatomical location into anterior and posterior uveitis or categorized by location of inflammation, e.g., iritis, pars planitis or iridocyclitis. Multiple drugs have been associated with ocular inflammation and much has been written on the subject. Discussed here is a sampling of drugs representing classes of medication associated with ocular inflammation. However, this is not a comprehensive list and interested readers are encouraged to access the National Registry of Drug-Induced Ocular Side Effects (Casey Eye Institute, Portland, Oregon, www.eyedrugregistry.com) or the textbook Drug-Induced Ocular Side Effects for further information (1). The agents discussed may be administered systemically, topically or intracamerally (inside the eye). The mechanism behind ocular inflammation is frequently unknown. Prevention and treatment are based upon physician recognition and withdrawal of the drug in some instances. Consultation with an ophthalmologist is recommended, as many types of ocular inflammation can threaten vision. Copyright (c) 2007 Prous Science. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17353948     DOI: 10.1358/dot.2007.43.2.1050789

Source DB:  PubMed          Journal:  Drugs Today (Barc)        ISSN: 1699-3993            Impact factor:   2.245


  2 in total

1.  Inflammatory ocular adverse events with the use of oral bisphosphonates: a retrospective cohort study.

Authors:  Mahyar Etminan; Farzin Forooghian; David Maberley
Journal:  CMAJ       Date:  2012-04-02       Impact factor: 8.262

Review 2.  Optimizing dosing frequencies for bisphosphonates in the management of postmenopausal osteoporosis: patient considerations.

Authors:  John Sunyecz
Journal:  Clin Interv Aging       Date:  2008       Impact factor: 4.458

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.